Understanding cerebral amyloid angiopathy becomes increasingly critical as populations age and dementia prevalence rises globally. This condition, where amyloid proteins accumulate in brain blood vessel walls rather than forming plaques, represents a distinct pathological pathway that intersects with but differs from Alzheimer's disease mechanisms. The vascular amyloid deposits compromise blood-brain barrier integrity and increase hemorrhage risk, creating unique diagnostic and therapeutic challenges.
The NEJM review synthesizes current knowledge about CAA's clinical presentation, which typically involves recurrent lobar hemorrhages in older adults, progressive cognitive decline, and characteristic neuroimaging patterns. Advanced MRI techniques now enable earlier detection through identification of microbleeds and cortical superficial siderosis. The condition affects approximately 50% of individuals over age 90, though many cases remain subclinical. Genetic variants, particularly in the APP gene, influence both sporadic and hereditary forms.
This comprehensive assessment arrives at a pivotal moment when CAA research is accelerating due to improved imaging capabilities and growing recognition of mixed pathologies in aging brains. The review likely consolidates recent advances in biomarker development and therapeutic targets, though CAA remains without specific treatments beyond managing associated conditions like hypertension. The clinical significance extends beyond neurology, as CAA influences decisions about anticoagulation therapy and stroke prevention strategies. While this appears to be a consolidating review rather than presenting novel findings, it serves the critical function of standardizing clinical approaches to a condition that was historically underdiagnosed but is now recognized as a major contributor to age-related brain dysfunction and hemorrhagic stroke risk.